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ABSTRACT 
ANTIDEPRESSANTS AND MELANOMA: IS THERE A LINK? Stephanie R. Douglas, Deepak Narayan. 
Section of Plastic and Reconstructive Surgery, Department of Surgery, Yale University School of 
Medicine, New Haven, CT. 
 
Cutaneous melanoma is the sixth most common cancer in the United States, and its incidence 
continues to rise steadily at a rate of 2-3% per year. Meanwhile nearly 11% of the general population is 
treated with antidepressant medication. Laboratory studies suggest a number of theoretical links between 
antidepressants and melanoma. Serotonin is a growth factor for melanocytes, and antidepressants 
upregulate components of the Wnt/beta-catenin, mTOR, and MAP kinase signaling pathways, all of which 
may be involved in melanoma transformation and carcinogenesis. To investigate the potential link between 
antidepressants and melanoma in vivo, localized tumors were induced in a conditional mouse model of 
BrafV600E-induced, Pten-deficient melanoma. Citalopram hydrobromide in 0.1% saccharin was administered 
at a dose of 20 mg/kg/day orally via drinking water beginning at the time of melanoma induction. Control 
animals received 0.1% saccharin. At weekly intervals, the overall tumor volume was assessed so that the 
tumor growth rate could be calculated for each mouse. At day 75 following tumor induction, necropsy was 
performed to assess for the presence of metastases. Antidepressant administration appeared to have no 
effect on tumor volume at any of the time points measured (day 29, p=0.997; day 36, p=0.761; day 44, 
p=0.612; day 50, p=0.682; day 57, p=0.797; day 66, p=0.691; day 75, p=0.736), or on metastasis. 
Secondly, the charts of 1271 patients treated for melanoma at Yale Cancer Center between 1997 and 2013 
were reviewed, taking particular note of medication history. A health history questionnaire eliciting 
information about melanoma risk factors as well as medication histories was administered to patients seen 
at an outpatient surgery clinic at Yale-New Haven Hospital who had no history of melanoma. Age, sex, and 
group (cases or controls) were entered into a binary logistic regression model to calculate an adjusted odds 
ratio for antidepressant exposure as a function of group. Additionally, age, sex, and tumor stage were 
entered into a second model for the odds of antidepressant exposure as a function of tumor stage. 
Melanoma patients were less likely to have a history of antidepressant use relative to controls (OR 0.567, 
95% CI 0.331-0.972, p=0.039). There was no association between antidepressants and melanoma stage at 
diagnosis. Further study is needed in order to clarify the nature of the association between antidepressants 
and melanoma risk.  
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INTRODUCTION 
 Cutaneous melanoma is the sixth most common cancer in the United States and 
the most common fatal malignancy that afflicts young adults. The incidence of melanoma 
continues to rise steadily at a rate of 2-3% per year. (1) Melanoma risk is affected by both 
genetic and environmental factors, the most salient of which are skin color, sun exposure, 
immunocompromised status, and a personal or family history of melanoma. In addition to 
these known risk factors, however, certain hormones and medications (e.g. oral 
contraceptives, voriconazole) are postulated to play a role. (2, 3) 
 Antidepressants are one category of medications commonly used in the general 
population, including patients with melanoma or those at high risk for the disease. Nearly 
10% of the general population is estimated to suffer from a mood disorder, and 
depression is the leading cause of disability in the United States for people between the 
ages of 15 and 44. (4, 5) Many of these patients are treated with antidepressant 
medication. Furthermore, use of antidepressant medication is not limited to the treatment 
of depression; these drugs are used to treat anxiety, chronic pain, and a variety of other 
conditions as well. According to National Health and Nutrition Examination surveys 
conducted in the years 2005-2008, antidepressants are used by nearly 11% of people over 
the age of 12. In some subsets of the population, the rate of antidepressant use may reach 
nearly 23%. (6)  
  Even with an extensive literature on antidepressants and overall cancer risk, the 
data are inconclusive. Adding to the uncertainty is the fact that few studies have directly 
investigated the effect of antidepressant exposure on melanoma incidence and prognosis. 
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Given the large number of people taking antidepressant medication and the potentially 
lethal nature of melanoma, any link between the two would be cause for grave concern. 
Serotonin and melanocytes 
Though there are many different classes of antidepressants, all are believed to 
affect serotonin pathways (Table 1, Appendix I). The most commonly prescribed 
antidepressants fall into the selective serotonin reuptake inhibitor (SSRI) or serotonin-
norepinephrine reuptake inhibitor (SNRI) classes.  These drugs increase the levels of 
neurotransmitters in the neural synapse by inhibiting the reuptake of serotonin (in the 
case of SSRIs) or both serotonin and norepinephrine (in the case of SNRIs) by the 
presynaptic neuron. Because of their favorable side-effect profile and relative safety in 
overdose, SSRIs are often first-line agents for the treatment of depression. Tricyclic 
antidepressants similarly inhibit reuptake of serotonin and norepinephrine, and 
monoamine oxidase inhibitors, or MAOIs, irreversibly inhibit the enzyme responsible for 
the breakdown of serotonin, norepinephrine, and dopamine. Even the atypical 
antidepressants are thought to have some effect on serotonin systems, though the 
importance of this in the efficacy of these drugs for treating depression is unknown. 
 Serotonin plays an important role in cutaneous physiology, and the skin is a site 
of both production and action of serotonin. Serotonin is synthesized from tryptophan in a 
reaction catalyzed by tryptophan hydroxylase, an enzyme that has been detected in 
biopsies of normal skin as well as normal melanocytes in culture and melanoma cell 
lines. Immunohistochemical studies have identified the presence of serotonin in 
epidermal and adnexal structures as well as within the dermis. (7, 8) The skin is also able 
to convert serotonin to melatonin, and functional receptors for serotonin and melatonin 
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are expressed in keratinocytes and fibroblasts, as well as melanocytes. (9) Melatonin 
activates pathways protective against oxidative stress, while serotonin has vasoactive and 
immunomodulating effects. (8) 
 Serotonin serves as a growth factor for many cell types, including hepatocytes, 
basal cells, fibroblasts, and smooth muscle cells. With regard to melanocytes, serotonin 
has been shown to either stimulate or inhibit cell proliferation depending on culture 
conditions. (7) Interestingly, the serum concentration of serotonin is elevated following 
exposure to ultraviolet light, which itself is the most important environmental risk factor 
for cutaneous malignancies. (10) 
 The precise mechanism of antidepressants’ effects on mood has not been 
completely elucidated. However, antidepressants are believed to stimulate neurogenesis 
in regions of the brain such as the hippocampus, and this may play a role in the 
antidepressant effects of these compounds. (11) As derivatives of the neural crest, 
melanocytes may be similarly affected by antidepressant drugs. 
Immunomodulatory effects of antidepressants 
 Immunosuppression is associated with a heightened risk for melanoma as well as 
a poorer prognosis. (12-14) Melanoma occurs at an increased rate in solid organ 
transplant recipients (RR 2.1-3.6), patients with lymphoma (RR 1.75-6.17) and patients 
with HIV (RR 2.6 [95% CI 1.9-3.6]). (15) 
SSRIs have been shown to cause impairment of immune function. Herpes simplex 
virus reactivation has been observed in a number of patients taking fluoxetine, which is 
thought to be related to problems with cell-mediated immunity. (16) Furthermore, 
antidepressants can trigger a lupus-like illness in some patients. (17) Fluoxetine and 
	   4 
amitriptyline have been shown to inhibit normal lymphocyte proliferation in vivo in a 
rodent model. (18) Due to the important role of the immune system in clearance of 
melanoma cells, drugs that compromise immune function could allow melanoma tumors 
to grow unchecked. 
Wnt/beta-catenin signaling 
 Antidepressants are known to interact with pathways that are thought to be 
involved in the pathogenesis of melanoma. The Wnt signaling pathway is involved in 
regulating cell proliferation and differentiation, and Wnt upregulation leads to 
carcinogenesis via activation of the β-catenin pathway. Increased Wnt2 is known to lead 
to carcinogenesis, and constitutive action of the Wnt/β-catenin pathway is commonly 
seen in melanoma. (19, 20) 
 At the same time, depressed subjects show decreased Wnt signaling in the 
prefrontal cortex, and this abnormal pattern is reversed with antidepressant treatment. 
(21) Antidepressants cause increased expression and function of components of the Wnt-
Fz-GSK3 pathway, and hippocampal overexpression of Wnt2 or downregulation of 
GSK3 induces antidepressant-like effects. (21, 22) Given the ability of antidepressants to 
influence Wnt signaling in cortical and limbic regions of the brain, these drugs may also 
act on melanocytes, which are cells of neural crest origin. 
mTOR activity 
 Mammalian target of rapamycin (mTOR) is a protein kinase responsible for 
regulating VEGF production and cell growth in response to signals indicating growth 
factor stimulation and nutrient availability. mTOR is activated in the majority of 
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melanomas and functions as a growth promoter. Immunostaining for phosphoribosomal 
protein S5, an indicator of mTOR activity, increases moving from benign nevus to 
melanoma in situ to invasive melanoma. (23) Inhibitors of mTOR have anti-mitotic and 
anti-angiogenic effects in melanoma and other cancers, and these qualities are being put 
to therapeutic use in a new class of drugs being developed for the treatment of melanoma. 
(24) 
 Meanwhile, depressed subjects show dysregulation of mTOR signaling, and there 
is some evidence to suggest that mTOR activation is required for antidepressant effects. 
(25) Ketamine, a fast-acting antidepressant, rapidly activates mTOR and increases 
synaptogenesis in the prefrontal cortex. (21, 26) Certain other antidepressants, including 
escitalopram, paroxetine, and tranylcypromine, activate mTOR as well. (27) Were this 
type of mTOR activation to occur within the cutaneous milieu, antidepressants could 
perhaps influence the incidence or clinical behavior of melanoma. 
MAP kinase signaling 
 The BRAF gene encodes a protein involved in regulating MAP kinase and ERK 
signaling, which is involved in cell division and differentiation. BRAF activating 
mutations are present in as many as 80% of nevi and 50% of melanomas, leading to 
activation of the MAP kinase pathway and increased production of VEGF and matrix 
metalloproteinases. (28, 29) The MAP kinase pathway is thought to be an important 
pathway in melanoma transformation. (30) Likewise, the pathway seems to be involved 
in depression and the response to antidepressant treatment, with acute blockade of MAP 
kinase signaling leading to a depressive phenotype in behavioral models of depression. 
	   6 
(31) In addition, disruption of the MAP kinase signaling cascade leads to inhibition of 
antidepressant effects. (21, 31) 
Antidepressants and cancer risk 
 Previous studies suggest a broad theoretical basis for an association between 
antidepressant medication and cancer risk. Many antidepressants are structurally similar 
to antihistamines and tamoxifen, which have known tumor-promoting ability. (32) SSRIs 
bind to growth-regulating intracellular histamine receptors associated with antiestrogen 
binding sites affecting the cytochrome P450 enzyme system, which is involved in the 
metabolism of carcinogens. (33, 34) 
Preclinical studies have shown that serotonin may mediate cell proliferation in 
colonic tumor cells, and inhibition of serotonin uptake results in suppression of cell 
proliferation. (35) Some authors have described a biphasic response curve for fluoxetine 
and amitriptyline with low concentrations stimulating pancreatic cancer, colorectal 
cancer, and glioma growth and high concentrations inhibiting the growth of tumors. (36) 
Clinical studies of antidepressants and cancer risk have yielded mixed results. 
(37) Most studies have shown no statistically significant difference in cancer risk 
following use of antidepressants from multiple drug classes. (38-42) However, a small 
number of studies have demonstrated an increased risk of epithelial ovarian cancer in 
association with tricyclic antidepressants. (43, 44) Still others have suggested that the 
effect of antidepressants with regard to breast, esophageal, and gastric cancer risk is 
dependent on the timing and duration of exposure. (45-47) 
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Antidepressants and melanoma: in vitro and animal literature 
A small number of animal studies have directly studied the effect of 
antidepressants on melanoma growth and metastasis in animal models. In a rodent model 
of in vivo melanoma growth, tumors showed a two-to-three-fold greater rate of growth in 
mice receiving daily intraperitoneal injections of fluoxetine or amitriptyline at clinically 
relevant doses as compared to a control group of animals not injected with an 
antidepressant. (18) 
Another study examined the effects of pretreatment with desipramine or 
fluoxetine on primary tumor growth, metastasis formation, and mortality rate in mice 
subsequently inoculated with B16F10 melanoma cells. (48) In young males, desipramine 
promoted development of metastases and increased the mortality rate in spite of 
inhibiting growth of the primary tumor. This prometastatic effect was associated with an 
increase in plasma levels of VEG-F and MMP-9. In aged animals, both antidepressants 
increased primary tumor growth and had a moderate stimulatory effect on metastasis 
formation. 
In contrast, a similar study examined the effect of intraperitoneally injected 
fluoxetine, desipramine, and mirtazapine in the B16F10 melanoma model and found that 
fluoxetine had a dramatic inhibitory effect on melanoma tumor growth. (49) In this study, 
desipramine tended to decrease tumor growth as well, while mirtazapine had no effect. 
Previous studies by this group on the effect of fluoxetine on growth of S19 melanoma in 
female DBA/2 mice showed that fluoxetine had an inhibitory effect when low doses of 
cells were inoculated subcutaneously, but that effect disappeared when higher number of 
cells were introduced. (50) 
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While antidepressants upregulate activity in a number of pathways associated 
with the pathogenesis of melanoma, they may also influence other pathways in ways that 
serve to inhibit tumor growth. For example, one of the reasons melanoma is poorly 
responsive to chemotherapy and radiation is that tumor cells constitutively express Akt, 
protecting them against apoptosis. Sertraline is a potent inhibitor of the phosphorylation 
of Akt, and in vitro studies have demonstrated that sertraline can cause induction of 
endoplasmic reticulum and death of melanoma cells. (51) When sertraline was 
administered to mice with A375 melanoma xenografts, the drug appeared to inhibit tumor 
growth in vivo, perhaps due to downregulation of Akt, though the results did not achieve 
statistical significance.  
Tricyclic antidepressants have likewise shown inhibitory effects on melanoma 
growth under certain conditions. Two cell lines and eight primary cell cultures from 
melanoma metastases were exposed to nortriptyline, clomipramine, and amitriptyline. All 
three drugs inhibited tumor cell growth, though nortriptyline was more active than the 
others. (52) 
Interestingly, fluoxetine has been shown to act as an antioxidant in the B16F10 
mouse model of melanoma, with fluoxetine preventing against melanoma-induced 
oxidative changes in the mouse spleen. (53) The implications of this in human disease are 
unknown. 
Antidepressants and melanoma risk in humans 
 To date, few studies have investigated the relationship between antidepressants 
and melanoma in humans. Unpublished data from a cohort of patients with melanoma 
treated in the Yale Melanoma Unit demonstrated a higher incidence of multiple 
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melanomas in patients being treated with an SSRI or SNRI, with multiple primary lesions 
in 15% of such patients as compared to the overall rate of 6.4% identified in a prior 
study. 
With conflicting data in the basic science literature and a paucity of data in human 
subjects, further study of the possible link between antidepressants and melanoma is 
clearly warranted. Antidepressants are widely prescribed to a large segment of the 
population for a variety of medical conditions. Thus, if antidepressants were to influence 
the incidence or progression of melanoma, the implications would be far-reaching, 
affecting treatment decisions not only for melanoma patients with coexisting depression 
but possibly also the larger body of patients with conditions for which antidepressants are 
often prescribed. 
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PURPOSE, HYPOTHESES, AND SPECIFIC AIMS 
 Despite the many theoretical links between serotonin and the development and 
progression of melanoma, the effect of antidepressants on the incidence and outcome of 
melanoma is unknown. By investigating the effect of citalopram on tumor latency, tumor 
number, and tumor growth trajectory in mice that are genetically programmed to develop 
melanoma, this study sheds light on an important question that remains poorly 
understood. The epidemiological component of the study serves as a first step to 
understanding the effect of antidepressants on melanoma risk in humans. Due to the 
growth-stimulatory effects of serotonin on melanocytes, the immunomodulatory effects 
of antidepressants, and the ability of antidepressants to interact with signaling networks 
(e.g. Wnt, mTOR, MAP kinase) in a way that may be favorable to melanoma 
tumorigenesis, we hypothesized that antidepressants may increase the risk for developing 
melanoma or may otherwise alter tumor growth characteristics. 
Aim 1: To investigate the effect of antidepressants on tumor growth rate in vivo using a 
mouse model of melanoma. 
 Antidepressants are known to affect a number of pathways thought to be involved 
in melanoma pathogenesis, and serotonin is a growth factor for melanocytes. Citalopram 
is a highly serotonergic antidepressant of the SSRI class and is widely used to treat 
depression and anxiety due to its favorable side-effect profile. The Braf/Pten melanoma 
model described below features tumors with genetic lesions that are common in human 
melanoma and offers control over the timing and location of tumor initiation. This study 
is the first to examine the effect of antidepressant medication on the growth 
characteristics of melanoma tumors arising in vivo. We hypothesized that citalopram 
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would enhance melanoma tumor growth, leading to an increased tumor growth rate in a 
mouse model of melanoma. 
Aim 2: To compare the prevalence of antidepressant use among patients treated for 
melanoma at Yale Cancer Center from 1997-2013 with that of control patients seen at an 
outpatient surgery clinic at Yale with no history of melanoma. 
 Preliminary review of data from a subset of patients treated at the Yale Melanoma 
Unit reveals a higher-than-average rate of antidepressant use as well as an increased 
number of patients with multiple primary melanomas among those taking 
antidepressants. We hypothesized that the melanoma patient population would exhibit a 
higher rate of antidepressant exposure (at or prior to the time of melanoma diagnosis) 
relative to an age- and sex-matched control population seen at an outpatient surgery clinic 
at Yale with no history of melanoma. 
Aim 3: To compare the rate of antidepressant exposure among melanoma patients with 
early melanoma tumors and those with more advanced disease who were treated at Yale 
Cancer Center from 1997-2013. 
Prior studies in animal models of melanoma have shown that antidepressants 
potentially affect not only the rate of growth of the primary tumor but also the propensity 
of the tumor to metastasize. We hypothesized that melanoma progression would be 
facilitated by the presence of antidepressants in patients taking these medications, such 
that melanoma patients presenting with late-stage disease would be more likely to have a 
history of antidepressant exposure. 
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METHODS 
Aim 1: Mouse model 
MELANOMA MODEL: The experiments in Aim 1 utilized the conditional mouse model of 
BrafV600E-induced, Pten-deficient melanoma described in Dankort et al. 2009 to 
investigate the effect of citalopram on melanoma growth parameters in vivo. (54) BRAF 
activating mutations are present in 80% of nevi and 50% of melanomas, forming the 
basis for this model. (54, 55) The combination of mutated BRAF and silencing of PTEN 
is found in 20% of melanomas. (55) The Braf/Pten melanoma model has been 
successfully used by investigators at Yale to study pharmacologic agents that influence 
signaling pathways implicated in the pathogenesis of melanoma. Because this model 
recapitulates the genetic lesions commonly found in human melanoma, the effect of 
pharmacologic agents on the development and progression of melanoma in these animals 
is thought to parallel the processes that occur in human patients with melanoma. BrafV600E 
cell lines derived from Braf/Pten mice have been shown to respond to inhibition of 
mTorc1 and MEK1/2 using rapamycin and PD325901, respectively, suggesting that the 
biological behavior of tumors in these animals is similar to that of melanoma tumors in 
humans. (54) 
 The Braf/Pten melanoma model allows localized tumors to be induced by topical 
application of 4-hydroxytamoxifen (4-HT), with 100% penetrance within 10 weeks 
(Figure 1). (55) In these animals, the Cre-recombinase::estrogen receptor (CreER) fusion 
protein is constitutively expressed in melanocytes by Tyr transgenic promoter elements. 
Exposure to 4-HT causes CreER to be released from Hsp90 and translocate to the 
nucleus, where it results in the removal of DNA sequences between loxP sites and 
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consequent activation or inactivation of the gene of interest (here, BRAF). (55) In prior 
rodent studies investigating the possible association between antidepressants and 
melanoma, mice received subcutaneous or intravenous injections of B16F10 mouse 
melanoma cells that had been grown in culture, or melanoma xenografts. (18, 48-51, 53) 
The Braf/Pten model more closely replicates the biology of melanoma in humans, and the 
clinical behavior of such tumors likely has greater relevance to the human population.  
 
 
Figure 1: Braf/Pten mouse model of melanoma 
Schematic showing induction of melanoma with 4-HT. The Cre-recombinase::estrogen 
receptor (CreER) fusion protein is constitutively expressed in melanocytes by Tyr 
transgenic promoter elements, Exposure to 4-HT causes CreER to be released from 
Hsp90 and translocate to the nucleus, where it results in removal of DNA sequences 
between loxP sites and subsequent activation or inactivation of the gene of interest.  
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 Animals were housed in groups of 1-3 animals per cage in a temperature-
controlled environment under a 12-hour light-dark cycle. Standard food and drinking 
water solutions (described below) were freely available. Animal experiments were 
performed in accordance with a protocol approved by the Institutional Animal Care and 
Use Committee at Yale University (IACUC protocol #2011-11211). 
TUMOR INDUCTION: One major advantage of the Braf/Pten model of melanoma is that 
tumor induction with 4-HT offers control over the timing and location of melanoma 
initiation. Melanoma was induced on the back skin of the animals by treating adult mice 
with topical administration of 1-2 µl of 1.9 mg/ml (5 mM) 4-HT at 3 weeks of age.  
DRUG ADMINISTRATION: Citalopram hydrobromide was chosen for these experiments 
because its high binding affinity for the serotonin transporter makes it highly selective for 
serotonin. In view of serotonin’s role as a growth factor for melanocytes, a highly 
serotonergic antidepressant was felt to be desirable for these experiments. Citalopram has 
been used extensively in rodent studies and is commonly prescribed for the treatment of 
depression and anxiety due to its favorable side-effect profile.  
 Antidepressant administration began at the time of tumor induction with 4-HT 
and continued until the study endpoint (outlined below) was reached (Figure 2). 
Citalopram hydrobromide (Sigma-Aldrich, St. Louis, MO) was administered orally via 
drinking water at a dose of 20 mg/kg/day to the animals in the experimental group. The 
drinking water solution contained 0.1% saccharin to mask the taste of the drug. Control 
animals received 0.1% saccharin. Animals were denied access to other sources of 
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drinking water. There were two animals in the control group receiving saccharin solution, 
while four animals received citalopram/saccharin solution. 
 
 
Figure 2: In vivo study design 
Tumor is induced by topical application of 4-hydroxytamoxifen when the mouse is 3 
weeks of age. Antidepressant/placebo administration begins at the time of tumor 
induction. Tumors reach 1 mm3 in size by 4 weeks post-tumor induction. Study endpoint 
is reached when tumor measures 2 cm3.  
4-HT 4-hydroxytamoxifen 
 
 Saccharin solution (0.1%) was prepared by adding 200 mg saccharin (Sigma-
Aldrich, St. Louis, MO) to 200 ml near-boiling water and stirring until dissolved. For the 
citalopram solution, 22 mg citalopram hydrobromide was added to the warm saccharin 
	   16 
solution to achieve a concentration of 0.11 mg/ml, and the solution was gently swirled 
until no visible solid remained. Solutions were allowed to cool to room temperature 
before being placed in the animals’ cages. Fresh drinking water solutions were prepared 
every five days. The concentration of drug in solution was calculated to achieve a dose of 
20 mg/kg/day assuming an average water intake of 6.7 ml/day per mouse and a weight of 
30 g per mouse.  
TUMOR ASSESSMENT: At weekly intervals, the overall tumor volume was assessed so that 
the tumor growth rate could be calculated for each mouse according to the following 
procedure: Each week, the maximal and minimal dimensions of each tumor were 
measured, along with tumor thickness. Tumor volumes (V) were calculated using the 
formula V=4/3πLWD, where L was the longer dimension of the tumor, W the smaller 
dimension, and D the depth. Aggregate tumor volumes were calculated for each animal 
as the sum of the volume of the individual tumors, and this was plotted against time in 
days since the first melanoma lesion became visible. 
STUDY ENDPOINT AND EVALUATION OF METASTASES: In accordance with the approved 
IACUC protocol, animals were euthanized by cervical dislocation when the largest 
melanoma tumor reached 2 cm3. Necropsy was performed on control and experimental 
animals immediately following euthanasia. Lymph nodes (bilateral axillary and inguinal), 
lungs, liver, spleen, and brain were removed and assessed for visible metastases. For 
larger structures such as the lungs, liver, and brain, organs were serially sectioned to 
allow for more thorough evaluation. Ears, paws, and tail were examined for the presence 
of cutaneous metastases as well. Owing to the difficulty of assessing the precise size of 
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the metastatic deposits, metastases were categorized as either “present” or “absent.”  
STATISTICAL ANALYSES: Tumor latency, tumor number, and tumor growth rate were 
expressed as a mean value ± standard deviation (SD). T-tests were performed to evaluate 
differences between experimental and control groups, and p-values of <0.05 were 
considered to be statistically significant. 
Aim 2: Case-control study 
MELANOMA PATIENTS: Patients were selected from among those presenting to Yale 
Cancer Center between the years of 1997 and 2013 with a diagnosis of melanoma. Yale 
Cancer Center is the largest melanoma treatment center in Connecticut and has a 
catchment area covering much of New England. Patients were drawn from the case logs 
of the two surgeons responsible for the vast majority of surgical therapy for patients with 
cutaneous melanoma presenting to Yale Cancer Center. Patients who did not receive 
surgical treatment of melanoma at Yale-New Haven Hospital (e.g. those referred to the 
medical oncologists for participation in a clinical trial) were excluded from the study. 
CONTROL SUBJECTS: Potential control subjects were identified from among patients and 
accompanying family members or friends presenting to two outpatient surgery clinics 
(orthopedic surgery and plastic surgery) at Yale University for reasons other than 
melanoma. Exclusion criteria included a personal history of prior melanoma and black 
race, due to the racial composition of the population of melanoma patients.  
DATA COLLECTION: Charts of melanoma patients were reviewed for demographic 
variables; cancer risk factors, including family history; medical and surgical history, 
including medication history; and details of the primary tumor (location and number of 
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primary tumors, Breslow depth, Clark level, tumor stage, histologic subtype, presence of 
BRAF mutations), treatment history, and disease course. When available, details of a 
patient’s antidepressant exposure were noted, including the particular medication used, 
the reason the antidepressant was prescribed, and the dose, timing, and duration of 
treatment. Patients whose charts did not contain a medication list were excluded from the 
study. Sun exposure data were not readily available in the patients’ charts. 
 Data collection began with the charts of all patients treated by the primary thesis 
advisor (DN). Data collection then proceeded alphabetically through the remaining charts 
due to the large number of patients treated by the senior surgeon during the selected time 
frame. A subset of charts was examined by a second reviewer to confirm the accuracy 
and completeness of the data being collected. 
 The chart review was approved by the Human Investigations Committee at Yale 
University and conducted in accordance with protocol # 0609001869. Charts were 
reviewed in hospital-designated reading rooms. No identifying information was collected. 
Data were stored in a password-protected file on a computer protected by university-
standard whole disk encryption accessible only by those conducting the chart review.  
 To obtain data from control subjects, an online health history questionnaire was 
administered in the waiting room of surgical subspecialty outpatient clinics (plastic 
surgery and orthopedic surgery) to patients and their accompanying family members or 
friends between August 2013 and January 2014. Questionnaires were administered using 
a laptop computer or an iPad belonging to a member of the research team. Participants 
were invited to take part in a research study “designed to learn more about the risk factors 
for melanoma.” Participants were not given any indication that the study was specifically 
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aimed at investigating antidepressant exposure as a cancer risk factor.  
 The full content of the health history questionnaire can be found in Appendix II. 
Briefly, the questionnaire included demographic information (age, city/state of residence, 
reason for presenting to clinic); melanoma risk factors (hair and eye color, skin tone, sun 
reaction); social history (tobacco and alcohol use, occupation); past medical history, 
including malignancy history; past surgical history; family history of malignancy. The 
questionnaire also directly queried subjects about current or past use of NSAIDs, 
anticoagulants, and antidepressants. 
STATISTICAL ANALYSES: Statistical analyses were performed using SPSS statistical 
software (IBM, Armonk, NY). Variables were first bivariately tested for differences 
between cases and controls using the chi-square test. Variables were then entered in a 
model of binary logistic regression, with antidepressants as the dependent variable and 
group as the first covariate. Age and sex were included in the second block of covariates 
to control for the effect of these variables. Results were expressed as an odds ratio with 
95% confidence interval, with p values <0.05 considered statistically significant. 
Aim 3: Melanoma cohort by stage 
DATA COLLECTION: Data collected from the melanoma patients according to the methods 
described under Aim 2 above was used to determine and compare the rate of 
antidepressant exposure among patients with early and late disease. For the first set of 
analyses, patients were first grouped into stage 0, I, II, III, and IV. Because the detailed 
pathology reports revealing the presence or absence of ulceration and number of mitoses 
were not always present in the patients’ charts, the A, B, and C subclassification was not 
specified. Data were then reanalyzed with patients divided into in situ, early-, and late-
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stage melanomas. Early melanomas were defined as stage I, while late melanomas were 
defined as stage II, III, or IV.  
STATISTICAL ANALYSES: Individual variables were initially tested using the chi-square 
test to determine any differences between groups. Binary logistic regression was then 
performed with antidepressant exposure as the dependent variable and age and sex as 
covariates. Tumor stage was included as a covariate in Block 2. Results were expressed 
as an odds ratio and 95% confidence interval, with p-values <0.05 considered statistically 
significant. SPSS software was used for these analyses. 	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RESULTS 
Aim 1: Mouse model 
  Weekly tumor measurements began on post-induction day 29. Aggregate tumor 
volumes for control and experimental animals are shown in Table 2. The volumes listed 
represent the sum of the volumes of the individual tumors for each animal.  
 
Table 2: Aggregate tumor volumes for control and experimental animals 
Days Post-
InductionA 
Aggregate Tumor Volume (mm3)B,C 
Control Experimental 
C1 C2 E1 E2 E3 E4 
29 129.35 82.65 24.35 2.07 99.11 297.22 
36 252.90 163.48 160.56 5.98 105.86 428.96 
44 352.86 217.07 118.79 21.24 105.96 579.00 
50 444.82 246.33 129.19 22.41 174.67 727.38 
57 550.41 265.75 328.44 42.16 389.79 1183.04 
66 1102.32 480.49 361.11 28.73 433.29 1551.65 
75 2200.49 477.64 545.13 41.96 706.01 2399.25 
A Refers to the number of days after melanoma was induced with 4-HT. 
B Tumor volumes (V) calculated using the formula V=4/3πLWD, where L was the longer dimension of the 
tumor, W the smaller dimension, and D the depth. 
C Aggregate tumor volume calculated as the sum of the volume of individual tumors. 
 
  Aggregate tumor volume was plotted against days following tumor induction for 
each animal to yield the chart shown in Figure 3 below. Animals C1 and E4 showed 
exponential tumor growth, whereas animals C2, E1, and E3 showed linear tumor growth 
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over the time period in which data were collected. Animal E2 demonstrated a very slow 
rate of tumor growth for the duration of the experiment. 
 
 
Figure 3: Melanoma growth trajectory in control and experimental animals 
C1, C2: control animals 
E1, E2, E3, E4: experimental animals 
 
 
  No difference was detected between control and antidepressant-exposed animals 
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Table 3: Student’s t-test for tumor growth 
  
  
Mean±SD   
Control (n=2) Experimental (n=4) p-value 
Day 29 106.00±33.02 105.67±134.26 0.997 
Day 36 208.19±63.23 175.34±180.79 0.761 
Day 44 284.97±96.02 206.25±252.24 0.612 
Day 50  345.58±140.35 263.41±315.82 0.682 
Day 57 408.08±201.29 485.86±488.86 0.797 
Day 66 791.40±439.71 593.70±662.49 0.691 
Day 75 1324.07±1239.45 923.09±1023.95 0.736 	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  By day 75, one animal from each group had reached the study endpoint of a tumor 
volume of 2 cm3, and all animals were euthanized. At the time of necropsy, four animals 
had evidence of cutaneous metastases at one or more location (ears—4, tail—3, paws—
1). Four animals had axillary lymph nodes that were grossly positive for melanoma 
(ipsilateral—3; contralateral—1). Lung metastases were present in one animal, and 
another animal had a single focus of metastasis in the brain. No animals showed evidence 
of grossly visible liver metastases. Cutaneous and nodal metastases were present in 
control and experimental animals, whereas only animals treated with antidepressants 
displayed evidence of visceral metastases (Table 4). 
 
Table 4: Patterns of metastases in control and experimental animals 
Location Control Experimental Total (# animals) C1 C2 E1 E2 E3 E4 
Ears X 
  
X X X 4 
Tail 
   
X X X 3 
Paws 
     
X 1 
Contralateral 



















   
1 
 
LN, lymph node 
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Aim 2: Case-control study 
The charts of 1412 melanoma patients were reviewed for this study. 141 patients 
were excluded because key information (medication list, date of melanoma diagnosis) 
could not be found in the patient’s chart. Thus, data from 1271 melanoma patients were 
included in the analyses. 
Ninety-eight control subjects agreed to participate in the study. Three subjects 
were excluded because they did not complete the health history questionnaire in its 
entirety or failed to provide data necessary for the analysis (e.g. age, gender, 
antidepressant history, melanoma history). Eight subjects were excluded due to black 
race so that the control population would more closely approximate the melanoma 
population. In total, 87 control subjects were included in the analysis. 
 Mean age was 59.4 ± 16.6 years for the melanoma patients and 48.8 ± 16.4 years 
for controls (Table 5). Of the melanoma patients, 635/1271 (50.0%) were female. Among 
controls, 57/87 (65.5%) were female. 
 
Table 5: Subject Characteristics 
Variable Cases (n=1271) Controls (n=87) p-value 
Age (mean ± SD) 59.4 ± 16.6  48.8 ± 16.4 <0.001 




  For both cases and controls, females were more likely to have been exposed to 
antidepressant medication (OR 2.148 [95% CI 1.564-2.950]; p<0.001). There was no 
significant effect of age on antidepressant exposure (OR 1.007 [95% CI 0.998-1.017]; 
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p=0.117). Among melanoma patients, 182/1271 (14.3%) had a history of antidepressant 
use, compared to 20/87 (23.0%) controls (Table 6). 
 
Table 6: Data for group and history of antidepressant use 
Antidepressant Exposure Melanoma  Patients Controls Total 
History of antidepressant use 182 20 202 
No history of antidepressant use 1089 67 1156 




 The logistical model with age and sex as covariates demonstrated that melanoma 
patients were less likely to have been exposed to antidepressant use prior to or at the time 
of melanoma diagnosis than were controls (OR 0.567 [95% CI 0.331-0.972]; p=0.039; 
Table 7). 
 
Table 7: Logistic regression analysis of antidepressant exposure among melanoma 
patients and controls 
Predictor β SE β 
Wald's 




Constant -2.165 0.381 32.214 1 <0.001 0.115 
 
Age 0.009 0.005 3.406 1 0.065 1.009 
 
Gender  
    (0=males,  















    (0=controls,  
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ANALYSIS WITH SEPARATE MODELS FOR MALES AND FEMALES: When the data were 
reanalyzed using separate models for males and females, age remained insignificant 
(males: OR 1.009 [95% CI 0.993-1.025]; p=0.283; females: OR 1.007 [95% CI 0.995-
1.018]; p=0.247). Among males, no association was seen between group (cases vs. 
controls) and antidepressant use (OR 0.658 [95% CI 0.219-1.982]; p=0.457). For 
females, an association between group and antidepressant use approached statistical 
significance, with melanoma patients less likely than controls to have a history of 
antidepressant exposure (OR 0.540 [95% CI 0.290-1.005]; p=0.052). 
 
Aim 3: Melanoma cohort by stage 
 Of the 1271 melanoma patients included in the analysis for Aim 2 (above), 1257 
patients had staging information available. The characteristics of the cohort are shown in                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
Table 8 (below).  
 Mean age of the subjects was 60.9 ± 15.6 years for stage 0 disease, 58.0 ± 16.3 for 
stage I, 64.5 ± 17.7 for stage II, 56.4 ± 17.1 for stage III, and 55.3 ± 17.7 for stage IV. Of 
subjects who presented with stage 0 disease, 176/313 (56.2%) were female. 348/675 
(51.6%) of stage I subjects were female, as were 61/177 (34.5%) of stage II subjects, 
35/72 (48.6%) of stage III subjects, and 9/20 (45.0%) of stage IV subjects (Table 9). 
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Table 8: Characteristics of the melanoma cohort (Aim 3). 
Variable Stage 0 Stage I Stage II Stage III Stage IV p-value 
 
























Table 9: Data for tumor stage at diagnosis. 
  Stage   
Sex 0 I II III IV Total 
Male 137 327 116 37 11 628 
Female 176 348 61 35 9 629 




 In the entire melanoma cohort, females were more likely to have been exposed to 
antidepressant medication (OR 2.067 [95% CI 1.485-2.877]; p<0.001). There was no 
significant effect of age on likelihood of antidepressant exposure (OR 1.008 [95% CI 
0.998-1.017]; p=0.127). 
 The logistical model with age and sex as covariates demonstrated that there was 
no effect of tumor stage on the likelihood of antidepressant exposure at the time of 
melanoma diagnosis (OR 0.945 [95% CI 0.784-1.139]; p=0.553; Table 10). 
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Table 10: Logistic regression analysis of antidepressant exposure among melanoma 
patients by tumor stage 
Predictor β SE β 
Wald's 





-2.568 0.359 51.060 1 <0.001 0.077 
Age 
 
0.008 0.005 2.287 1 0.130 1.008 
Gender  
    (0=males,  
    1=females) 
 
0.717 0.169 17.904 1 <0.001 2.048 
Tumor stage  
    (0=MIS,  
    1=stage I,  
    2=stage II,  
    3=stage III,  
    4=stage IV) 
 





Figure 5: Percentage of melanoma patients with history of antidepressant use at time of 
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ANALYSIS OF EARLY VERSUS LATE AND IN SITU VERSUS INVASIVE LESIONS:  When the 
melanoma cohort was divided into patients with melanoma in situ, early (stage I), or late 
(stage II-IV) disease, logistic regression demonstrated no effect of tumor stage on 
likelihood of antidepressant use before or at the time of melanoma diagnosis (OR 0.921 
[95% CI 0.728-1.165]; p=0.492). Similarly, no differences in likelihood of antidepressant 
use were found when classifying patients as having in situ (stage 0) or invasive (stage I-
stage IV) disease (OR 0.976 [95% CI 0.680-1.402]; p=0.895). 
ANALYSIS USING SEPARATE MODELS FOR MALES AND FEMALES:  When males and females 
were analyzed separately, there was no association between age and antidepressant use 
among males (OR 1.013 [95% CI 0.996-1.031]; p=0.130) or females (OR 1.005 [95% CI 
0.993-1.017]; p=0.432). Males had a mean age of 62.07±15.87. Females had a mean age 
of 56.74±16.98. Melanoma stage at diagnosis was not a significant predictor of prior or 
concurrent antidepressant use for either males (OR 1.125 [95% CI 0.847-1.493]; 
p=0.417) or females (OR 0.835 [95% CI 0.650-1.073]; p=0.159). 
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DISCUSSION 
 To our knowledge, this is the first study to investigate the effect of an 
antidepressant on melanoma growth characteristics using an animal model that closely 
parallels human melanoma. Previously, other studies that attempted to address the issue 
of antidepressants and melanoma in vivo utilized melanoma models that do not replicate 
tumor biology, such as subcutaneous injection of melanoma cells grown in culture. 
Despite the small sample size, this project demonstrates the feasibility of administering 
antidepressants to melanoma-bearing mice via the drinking water and conducting weekly 
assessments of tumor volume.  
 In this experiment, oral citalopram at a dose of 20 mg/kg/day did not appear to 
affect the growth rate of melanoma tumors. Looking at Figure 3, there appear to be three 
distinct patterns of tumor growth: tumors in animals C1 and E4 showed exponential 
growth; C2, E1, and E3 showed linear growth over the time course of the experiment; 
and E2 had a relatively small tumor burden when the study endpoint was reached. 
Grossly, these patterns do not appear to correlate with antidepressant exposure. With 
marked variability in the patterns of growth between the two control animals that were 
tested, a larger sample size would be needed in order to draw firm conclusions about the 
effect of citalopram on tumor growth. 
Citalopram was chosen for these experiments because it is a highly serotonergic 
antidepressant.  However, other antidepressants may influence the growth characteristics 
of melanoma in different ways, or by different mechanisms. Thus, future studies could 
involve testing other SSRIs or different classes of antidepressants in the Braf/Pten mice. 
The 20 mg/kg/day dose of citalopram was in line with other rodent studies of 
	   32 
antidepressants in the psychiatry literature, but those studies were primarily interested in 
the CNS effects of antidepressants. Citalopram (and other antidepressants, as well) are 
metabolized differently by mice than by humans, and the action of antidepressants in the 
skin may vary across species as well; thus, different drug doses may be needed to achieve 
a bioequivalent effect in humans and in mice. 
Furthermore, the patterns of antidepressant exposure in this experiment differ 
markedly from the ways in which such medications are typically used in humans. Often, 
patients with psychiatric diagnoses or chronic pain are maintained on antidepressant 
medication for many years prior to presenting with melanoma. The short exposure 
duration for the animals in this experiment may have been insufficient to generate an 
effect on tumor growth. Additionally, antidepressant exposure in the mice began 
simultaneously with tumor induction, whereas antidepressant use in humans frequently 
precedes melanoma tumorigenesis. In future studies, animals could be treated with 
antidepressants from birth, rather than beginning at the time of tumor induction. 
Importantly, the study presented here did not assess tumor latency in control 
versus experimental animals, and this may in fact be an important parameter of interest. 
Tumor incidence and tumor growth rate may be quite different issues. Because the 
Braf/Pten mice develop melanoma with 100% penetrance, an effect of antidepressants on 
tumor incidence would be obscured. Tumor latency in the Braf/Pten mouse model might 
be a useful surrogate marker for tumor incidence in humans, as prolonging tumor latency 
in humans would give the immune system a better chance to mount a response against 
malignant cells. 
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Though the study was principally designed to investigate the effect of 
antidepressants on growth of the primary tumor, organs were visually assessed 
macroscopically for metastases. Histologic assessment could be employed in the future to 
more accurately determine the presence and/or size of metastatic deposits. With only 
two-to-three animals per experimental group involved in this experiment and the 
potential for a large number of possible combinations of visceral metastases, the results 
presented here must be viewed as inconclusive. 
In the event that future studies demonstrate an effect of antidepressants on tumor 
growth characteristics, future work could be directed at clarifying the molecular pathways 
responsible for the association between antidepressants and melanoma. Two additional 
mouse models of melanoma are available at Yale, each with distinct genetic lesions 
resulting in tumors that show different clinical behavior. Investigating the differential 
effects of antidepressants on animals with different genetic backgrounds could shed light 
on the pathways through which antidepressants operate in malignant melanoma.  
  The results of the case-control analysis failed to support the hypothesis that 
melanoma patients would have a higher rate of antidepressant exposure than controls. 
Indeed, controls were 1.76 times more likely than melanoma patients to have taken 
antidepressant medication. This result is in line with some of the pre-clinical data and at 
odds with others. (7, 18, 48-53) While the study presented here represents a good first 
step toward characterizing the possible association between antidepressants and 
melanoma risk, the following methodological considerations may have impacted the 
study outcome. 
 One of the most important methodological challenges in designing a case-control 
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study such as the one presented here is deciding on an appropriate control group. Ideally, 
control subjects would be matched to melanoma patients according to race, age, and sex, 
at a minimum. Because the control group was younger and more female than the 
melanoma cases, age and sex were entered into the binary logistic regression model to 
correct for the differences statistically. However, this technique can obscure the effect of 
an exposure when it is strongly correlated with other variables in the model. Here, 
antidepressant use strongly correlated with female sex, so the analysis was repeated for 
males and females separately. No qualitative differences were observed in the repeat 
analysis. 
 Unfortunately, the patient’s race was often not explicitly specified in the 
melanoma patients’ charts, so the racial makeup of the melanoma cohort was not reported 
in this manuscript. However, melanoma is known to be largely a disease of whites, 
affecting only a miniscule number of non-white individuals. In order to maximize the 
number of controls available for the analysis, Hispanic subjects were included in the 
control group. The cases included a small proportion of subjects whose ethnicity was 
documented as Hispanic, but the proportion of Hispanic controls likely exceeded the 
proportion of Hispanic cases.  
 One risk factor that is of the utmost importance in melanoma is sun exposure. Sun 
exposure is incredibly difficult to quantify, particularly since the relevant exposure may 
occur rather remotely, such as in childhood. Studies attempting to quantify lifetime sun 
exposure have used a variety of methods, most relying on detailed surveys or 
questionnaires asking subjects to report the geographical locations in which they lived at 
various stages of life, as well as details of their occupation and leisure-time activities. 
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(56-59) Though a small subset of charts in this study contained information on the 
number of sunburns the patient had experienced, this information was insufficient to 
characterize overall sun exposure history. Thus, no attempt was made to match cases and 
controls for a history of sun exposure in this study. 
 In an effort to minimize the impact of physician practice patterns on the rate of 
antidepressant exposure in the two groups, a hospital-based control group was selected. 
Previous case-control studies investigating melanoma risk factors have used population-
based controls recruited by means of random-digit dialing, population registries, and the 
like. (56, 57) Hospital-based controls were thought to be more reflective of the 
population presenting to Yale Cancer Center for treatment of melanoma. 
 Notably, the rates of antidepressant use in the control population presented here 
far exceeded the rates reported in the literature for the population as a whole, nationwide. 
(6) One thing that remains unanswered is whether this difference in rates of 
antidepressant use reflects a difference in prescribing habits of primary care physicians 
and psychiatrists in Connecticut as compared to the United States overall, or whether 
there was in fact something unrepresentative about patients presenting to the plastic 
surgery and orthopedic surgery outpatient clinic at Yale and/or those who elected to 
participate in the study. The subjects recruited from plastic surgery clinic included 
patients being seen in consultation or follow-up for both reconstructive and cosmetic 
surgical procedures. Cosmetic surgery patients may be more likely to carry psychiatric 
diagnoses and thus more likely to have been treated with antidepressants than the general 
population. (60-62) Similarly, reconstructive surgery practices often serve a population of 
medically complex, sicker patients, in comparison with the healthier, more active patients 
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who sustain orthopedic injuries or develop melanoma after years of sun exposure. Sicker 
patients may have higher rates of depression, or they may simply have a greater number 
or frequency of contacts with the healthcare system and thus a higher likelihood of being 
started on antidepressant medication. 
 Another methodological weakness of the study presented here is that 
antidepressant exposure was ascertained in different ways for cases and controls; for 
melanoma patients, information was collected via chart review, whereas control subjects 
were queried directly about their medical history and drug exposures. On one hand, 
people may be more willing to reveal sensitive information, such as a history of 
antidepressant use, to their doctors than to a member of the research staff with whom they 
have no preexisting relationship. Questionnaires were completed anonymously, but 
subjects may still have had reservations about volunteering information of a personal 
nature that seemed irrelevant to their care. On the other hand, the questionnaires 
completed by control subjects explicitly asked about antidepressant use, whereas the 
physician may have only asked about medications in more general terms. The methods 
utilized in this study were chosen for their feasibility in the setting of limited resources, 
but the method of data acquisition would have ideally been the same for cases and 
controls. 
 The data presented here failed to demonstrate an association between 
antidepressant use and melanoma stage at the time of diagnosis. This pattern held true 
whether patients were grouped into three or five categories of stages, as well as when 
they were divided into groups based on the presence of in situ or invasive disease.  
Neither males nor females showed an effect of tumor stage on likelihood of 
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antidepressant exposure. Based on the results of the case-control analysis, any interaction 
between antidepressant exposure and melanoma pathogenesis is presumed to be weak 
and confounded by a multitude of variables. Thus, this study may not have been 
adequately powered to detect an association when dividing the melanoma cohort into 
multiple groups. 
  With limited knowledge of the precise mechanism by which antidepressants 
interact with melanoma risk, the relevant details of antidepressant exposure are uncertain. 
Other studies in the cancer literature have found effects of antidepressants that were 
dependent on dose and duration of treatment, as well as the timing of exposure (i.e. 
temporal proximity to cancer diagnosis). Unfortunately, these details were often not 
available in the medical record, so for the present study, patients were categorized as 
“antidepressant exposed” if they had a record of current or past antidepressant treatment 
documented in the chart at the time of melanoma diagnosis. Likewise, the indication for 
treatment with an antidepressant would be important to consider when making 
recommendations about how to manage melanoma patients on antidepressants, should 
further study reveal a deleterious effect on prognosis, but this information was only 
infrequently recorded in the chart. 
  While it would be desirable to characterize the specific details of subjects’ 
antidepressant use, it may not be practical to contact subjects individually when dealing 
with a large cohort of patients, and in some cases, it would not be possible due to death of 
a patient or incorrect contact information. Implementation of the electronic medical 
record for both inpatient and outpatient visits may yield a powerful tool for more 
accurately assessing a subject’s past or present use of antidepressants or other 
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medications. Having a centralized medication list that is accessed by all providers may 
improve the chances that the charts of sick and non-sick patients alike will contain a 
complete medication list, and linking the chart with pharmacy records would provide a 
metric for determining whether patients are actually taking the medications that are 
prescribed to them. 
An important consideration when it comes to evaluating the hypothesis that 
antidepressants might increase melanoma risk is whether there might be an underlying 
association between cancer risk and depression itself. Here, the data are conflicting. 
Depression is characterized by a proinflammatory state reflected by elevated plasma 
levels of circulating cytokines that could contribute to neoplastic growth. (63) 
Furthermore, a 1998 study of 4825 people over 71 years of age concluded that depression 
of at least six years’ duration was associated with increased cancer mortality. (64) 
However, a majority of prospective studies point to a weak relationship or none at all 
between depression and overall cancer risk. (63, 65-70) Other studies claimed an 
increased cancer risk in depressed patients but failed to account for major confounders, 
including smoking. (71) 
The relationship between depression and melanoma is poorly understood and 
undoubtedly complex. Sun exposure increases plasma levels of serotonin, and patients 
with mild depression may self-medicate by spending a greater amount of time in the sun. 
(10) Conversely, severely depressed patients may lack the energy or motivation to leave 
their homes and therefore have decreased sun exposure. For patients with a long history 
of depression, the effect of mood on sun exposure could perhaps be enough to impact 
overall melanoma risk. Interestingly, one group has shown that 46% of patients with 
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melanoma had a major life crisis in the five years preceding melanoma diagnosis, 
suggesting that stress may play a role. (72) However, the authors point out that these data 
must be interpreted with caution, as people may be more likely to consult a health 
practitioner following a stressful event, leading to an increase in melanoma diagnoses. 
In the setting of unlimited resources, one way to address the issue of depression as 
a confounding factor in the interaction between antidepressants and melanoma would be 
to eliminate depression as a variable. This could be done by studying exclusively 
depressed subjects with and without a history of treatment with antidepressant 
medication, or by excluding patients with depression so that the antidepressant-exposed 
population would have been prescribed antidepressants for only non-psychiatric reasons. 
To achieve a sufficient number of subjects, such an effort would likely need to be multi-
institutional. 
Though the data presented here failed to uncover evidence in support of a causal 
link between citalopram and melanoma tumorigenesis, these results must be considered 
preliminary in nature. Further study is warranted, given the limitations of the project 
presented here. Chart review is ongoing, and we hope to include all patients at Yale 
treated surgically for melanoma in future studies on the effect of antidepressants on 
melanoma incidence and disease course.  
A related question to investigate in the future is whether the proportion melanoma 
patients with BRAF-mutant tumors differs between those with and without a history of 
antidepressant exposure. BRAF is the most common genetic mutation found in 
melanoma, and BRAF mutations are also found at high frequency in benign nevi. Insofar 
as antidepressants may facilitate malignant transformation, the effect likely occurs only 
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atop a background of genetic mutations. Thus, one would expect to see a higher 
proportion of tumors from patients with antidepressant exposure carrying BRAF 
mutations, suggesting that they arose from a preexisting nevus. 
In the event that further study demonstrates an effect of antidepressants on 
melanoma incidence, tumor growth kinetics and/or disease prognosis, the results could 
have ramifications for treatment of depression and the other conditions for which 
antidepressants are prescribed, particularly in patients diagnosed with melanoma. The 
possible implications of this line of research are made even more significant by the sheer 
number of patients using antidepressant medication. Evaluation of the hypothesis 
outlined in this paper potentially stands to inform the care of the many thousands of 
patients each year treated for depression, anxiety, chronic pain or various other medical 
conditions. 
If, on the other hand, antidepressants prove to have an inhibitory effect on 
melanoma incidence, growth, and metastasis, perhaps the beneficial effects of these 
compounds could be harnessed and utilized in the treatment of melanoma or in the 
prevention of disease in high-risk groups. 
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APPENDIX I 
Table 1: Classes of antidepressant medication 







Serotonin-norepinephrine reuptake inhibitors (SNRIs) 
 











amitriptyline (Tryptomer, Elavil, Endep) 
clomipramine (Anafranil) 
desipramine (Norpramin, Pertofrane) 
doxepin (Adaptin, Sinequan) 
imipramine (Tofranil, Janimine, Praminil) 
nortriptyline (Pamelor, Aventyl, Norpress) 
Monoamine oxidase inhibitors (MAOIs) 
 
phenelzine (Nardil) 
selegiline (Eldepryl, Emsam, Zelapar) 
tranylcypromine (Parnate) 
 
A not available in the United States 
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APPENDIX II 




2.  Age: 
3. Place of residence (City/Town, State): 
4. Reason for coming into clinic: 
5. Height (feet, inches): 
6. Weight (lbs): 
7. Occupation: 





○ American Indian or Alaskan Native 
○ Native Hawaiian or Pacific Islander 
9. Skin tone:  





○ Very dark brown 
10. Hair color: 
11.  Eye color: 
12. How does your skin react to the first summer sun exposure of the year? 
○ Always burns, never tans 
○ Usually burns, tans with difficulty 
○ Sometimes burns, usually tans 
○ Rarely burns, tans easily 
○ Very rarely burns, tans very easily 
○ Never burns 
13. How many blistering sunburns have you experienced? 
14. How many non-blistering sunburns have you experienced? 
15. Do you sunbathe or use tanning oil or tanning beds? 
○ Yes, currently 
○ Yes, in my youth 
○ Both 
○ Neither 
16. Smoking history: 
○ I currently smoke 
○ I used to smoke but do not currently 
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○ I have never smoked 
17. If yes to 16: How many packs per day (on average)? 
18. If yes to 16: For how many years? 
19. How many alcoholic beverages do you drink in a typical week? 
20. Have you ever been told you have any of the following medical conditions? 
○ High blood pressure 
○ High cholesterol 
○ Diabetes 
○ Heart disease 
○ Hyperthyroidism (overactive thyroid) 
○ Hypothyroidism (underactive thyroid) 
○ Atrial fibrillation 
○ DVT (blood clot in leg or arm) 
○ Stroke 





○ Autoimmune disease (rheumatoid  
     arthritis, lupus, scleroderma, etc.) 
○ Eczema 
○ Psoriasis 
○ Kidney disease 
○ Liver disease 
21. Please list any medical conditions you have that are not listed above. 
22. Please list the type of surgery and the year of surgery for any surgical procedures you have had, or 
write “none” if you have never had surgery. 
23. Do you take any of the following anti-inflammatory medications? 
 
24. Have you ever taken steroid medications by mouth (e.g. prednisone) or other medications that 
suppress your immune system? (Do not include topical or inhaled medications, such as creams, 
ointments, or inhalers.) 
○ No 
○ Yes, short-term (less than 2 weeks) 
○ Yes, long-term (greater than 2 weeks) 
25. Have you ever taken blood thinners (e.g. warfarin, Coumadin, Lovenox)? 
○ Currently taking 
○ Have taken in the past 
○ Have never taken 
26. Please give the name of medication, dose, start date, and stop date (if applicable) for blood thinners 
you have taken, or write “N/A” if you have never taken blood thinners or “unsure” if you do not 
know the requested information. 
27. Have you taken any of the following medications which are sometimes used to treat depression, 
anxiety, chronic pain, or migraine headaches? 
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28. Please give the dose, start date, and stop date (if applicable) for any of the antidepressant medications 
listed above, along with the name of any antidepressants you have taken that are not listed. Write 
“N/A” if you have never taken antidepressant medication or “unsure” if you do not know the 
requested information. 
29. Have you ever been prescribed thyroid medication (e.g. Synthroid, Levoxyl, levothyroxine, Cytomel, 
Thyrolar, Armour thyroid)? 
○ Yes 
○ No 
30. Please list any other medications you currently take, along with the dose and frequency (if known). 
Include vitamins or herbal supplements you take, as well. 
31. Have you ever had a suspicious mole removed? 
○ Yes 
○ No 
32. Have you ever been diagnosed with melanoma? 
○ Yes 
○ No 
33. Have you ever been diagnosed with a non-melanoma skin cancer (e.g. basal cell carcinoma, 
squamous cell carcinoma)? 
○ Yes 
○ No 
34. Have you ever been diagnosed with another type of cancer? 
○ Yes 
○ No 
35. If yes to 34: Please indicate the type of cancer and your age at diagnosis. 
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36. Has anyone in your family been diagnosed with melanoma? 
○ Yes 
○ No 
37. If yes to 36: Please indicate which of your relatives was diagnosed with melanoma. 
38. Has anyone in your family been diagnosed with another type of cancer besides melanoma? 
○ Yes 
○ No 
39. If yes to 38: Please indicate the type of cancer and which of your relatives was affected. 	  
 	  
